Cargando…

Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic

The discovery of antifibrotic agents have resulted in advances in the therapeutic management of idiopathic pulmonary fibrosis (IPF). Currently, nintedanib and pirfenidone have become the basis of IPF therapy based on the results of large randomized clinical trials showing their safety and efficacy i...

Descripción completa

Detalles Bibliográficos
Autores principales: Serra López-Matencio, José M., Gómez, Manuel, Vicente-Rabaneda, Esther F., González-Gay, Miguel A., Ancochea, Julio, Castañeda, Santos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400767/
https://www.ncbi.nlm.nih.gov/pubmed/34451916
http://dx.doi.org/10.3390/ph14080819
_version_ 1783745392789159936
author Serra López-Matencio, José M.
Gómez, Manuel
Vicente-Rabaneda, Esther F.
González-Gay, Miguel A.
Ancochea, Julio
Castañeda, Santos
author_facet Serra López-Matencio, José M.
Gómez, Manuel
Vicente-Rabaneda, Esther F.
González-Gay, Miguel A.
Ancochea, Julio
Castañeda, Santos
author_sort Serra López-Matencio, José M.
collection PubMed
description The discovery of antifibrotic agents have resulted in advances in the therapeutic management of idiopathic pulmonary fibrosis (IPF). Currently, nintedanib and pirfenidone have become the basis of IPF therapy based on the results of large randomized clinical trials showing their safety and efficacy in reducing disease advancement. However, the goal of completely halting disease progress has not been reached yet. Administering nintedanib with add-on pirfenidone is supposed to enhance the therapeutic benefit by simultaneously acting on two different pathogenic pathways. All this becomes more important in the context of the ongoing global pandemic of coronavirus disease 2019 (COVID-19) because of the fibrotic consequences following SARS-CoV-2 infection in some patients. However, little information is available about their drug–drug interaction, which is important mainly in polymedicated patients. The aim of this review is to describe the current management of progressive fibrosing interstitial lung diseases (PF-ILDs) in general and of IPF in particular, focusing on the pharmacokinetic drug-drug interactions between these two drugs and their relationship with other medications in patients with IPF.
format Online
Article
Text
id pubmed-8400767
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84007672021-08-29 Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic Serra López-Matencio, José M. Gómez, Manuel Vicente-Rabaneda, Esther F. González-Gay, Miguel A. Ancochea, Julio Castañeda, Santos Pharmaceuticals (Basel) Review The discovery of antifibrotic agents have resulted in advances in the therapeutic management of idiopathic pulmonary fibrosis (IPF). Currently, nintedanib and pirfenidone have become the basis of IPF therapy based on the results of large randomized clinical trials showing their safety and efficacy in reducing disease advancement. However, the goal of completely halting disease progress has not been reached yet. Administering nintedanib with add-on pirfenidone is supposed to enhance the therapeutic benefit by simultaneously acting on two different pathogenic pathways. All this becomes more important in the context of the ongoing global pandemic of coronavirus disease 2019 (COVID-19) because of the fibrotic consequences following SARS-CoV-2 infection in some patients. However, little information is available about their drug–drug interaction, which is important mainly in polymedicated patients. The aim of this review is to describe the current management of progressive fibrosing interstitial lung diseases (PF-ILDs) in general and of IPF in particular, focusing on the pharmacokinetic drug-drug interactions between these two drugs and their relationship with other medications in patients with IPF. MDPI 2021-08-20 /pmc/articles/PMC8400767/ /pubmed/34451916 http://dx.doi.org/10.3390/ph14080819 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Serra López-Matencio, José M.
Gómez, Manuel
Vicente-Rabaneda, Esther F.
González-Gay, Miguel A.
Ancochea, Julio
Castañeda, Santos
Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
title Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
title_full Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
title_fullStr Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
title_full_unstemmed Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
title_short Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
title_sort pharmacological interactions of nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis in times of covid-19 pandemic
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400767/
https://www.ncbi.nlm.nih.gov/pubmed/34451916
http://dx.doi.org/10.3390/ph14080819
work_keys_str_mv AT serralopezmatenciojosem pharmacologicalinteractionsofnintedanibandpirfenidoneinpatientswithidiopathicpulmonaryfibrosisintimesofcovid19pandemic
AT gomezmanuel pharmacologicalinteractionsofnintedanibandpirfenidoneinpatientswithidiopathicpulmonaryfibrosisintimesofcovid19pandemic
AT vicenterabanedaestherf pharmacologicalinteractionsofnintedanibandpirfenidoneinpatientswithidiopathicpulmonaryfibrosisintimesofcovid19pandemic
AT gonzalezgaymiguela pharmacologicalinteractionsofnintedanibandpirfenidoneinpatientswithidiopathicpulmonaryfibrosisintimesofcovid19pandemic
AT ancocheajulio pharmacologicalinteractionsofnintedanibandpirfenidoneinpatientswithidiopathicpulmonaryfibrosisintimesofcovid19pandemic
AT castanedasantos pharmacologicalinteractionsofnintedanibandpirfenidoneinpatientswithidiopathicpulmonaryfibrosisintimesofcovid19pandemic